Return to Listing

13 result(s) for Melanoma

PI Name Protocol # Title
Sancy Leachman IRB00010561 War on Melanoma: Enlisting a cohort of melanoma survivors and their families
Jacqueline Vuky IRB00011804 A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
Sancy Leachman STUDY00015038 Melanoma Tissue Bank Consortium: A Multi-Center Repository of Biospecimens and Data for Future Use
Prakash Ambady STUDY00016046 Response Assessment to Pembrolizumab with Standard of Care Therapy in Oligometastatic Brain Tumors from Melanoma, and Glioblastoma Using Ferumoxytol Steady State Imaging– A Pilot Study
John Vetto STUDY00017104 DecisionDx-Melanoma 31-Gene Expression Profile Clinical Impact Study
Rajan Kulkarni STUDY00017648 VAPORHCS/OHSU J: Isolation and analysis of circulating tumor cells (CTCs) and nucleic acids from patient blood specimens
Aimee Kohn STUDY00019207 A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Participants with Advanced Melanoma (LEAP-003)
Dale Han STUDY00019285 A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination with Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma
Aimee Kohn STUDY00019667 A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis
Aimee Kohn STUDY00019679 ADJUVANT THERAPY WITH PEMBROLIZUMAB VERSUS PLACEBO IN RESECTED HIGHRISK STAGE II MELANOMA: A RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY (KEYNOTE 716)
Aimee Kohn STUDY00019746 A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma
Aimee Kohn STUDY00019943 A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF RO7198457 IN COMBINATION WITH PEMBROLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED MELANOMA
Christopher Ryan STUDY00019992 [NCI CIRB] MATCH - EAY131 - Molecular Analysis for Therapy Choice (MATCH)
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080